6,322 Shares in Sanofi (NASDAQ:SNY) Bought by GF Fund Management CO. LTD.

GF Fund Management CO. LTD. acquired a new position in shares of Sanofi (NASDAQ:SNY - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 6,322 shares of the company's stock, valued at approximately $305,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Barclays PLC lifted its stake in Sanofi by 107.5% during the third quarter. Barclays PLC now owns 639,772 shares of the company's stock worth $36,869,000 after purchasing an additional 331,445 shares during the period. SG Americas Securities LLC lifted its position in shares of Sanofi by 19.5% during the 4th quarter. SG Americas Securities LLC now owns 18,008 shares of the company's stock worth $869,000 after buying an additional 2,940 shares during the period. Janney Montgomery Scott LLC boosted its stake in Sanofi by 5.9% in the 4th quarter. Janney Montgomery Scott LLC now owns 327,631 shares of the company's stock valued at $15,802,000 after buying an additional 18,279 shares in the last quarter. Brighton Jones LLC grew its position in Sanofi by 52.6% in the fourth quarter. Brighton Jones LLC now owns 5,420 shares of the company's stock valued at $261,000 after acquiring an additional 1,869 shares during the period. Finally, Stablepoint Partners LLC raised its stake in Sanofi by 4.9% during the fourth quarter. Stablepoint Partners LLC now owns 25,063 shares of the company's stock worth $1,209,000 after acquiring an additional 1,170 shares in the last quarter. 14.04% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on the stock. Deutsche Bank Aktiengesellschaft raised shares of Sanofi from a "sell" rating to a "hold" rating in a report on Thursday, January 30th. BNP Paribas initiated coverage on shares of Sanofi in a research note on Tuesday, April 15th. They set an "outperform" rating and a $65.00 price objective on the stock. Sanford C. Bernstein upgraded shares of Sanofi to a "strong-buy" rating in a research note on Thursday, January 30th. The Goldman Sachs Group began coverage on Sanofi in a report on Friday, March 21st. They issued a "neutral" rating and a $65.00 target price on the stock. Finally, Hsbc Global Res raised Sanofi to a "strong-buy" rating in a report on Monday, April 28th. Three equities research analysts have rated the stock with a hold rating, two have given a buy rating and three have assigned a strong buy rating to the stock. Based on data from MarketBeat, Sanofi presently has a consensus rating of "Buy" and an average target price of $63.33.

Sanofi Price Performance

Shares of SNY traded down $2.99 during mid-day trading on Friday, hitting $49.36. 2,631,393 shares of the company traded hands, compared to its average volume of 2,389,148. The business has a 50-day moving average of $52.37 and a 200 day moving average of $51.91. Sanofi has a one year low of $45.80 and a one year high of $60.12. The company has a current ratio of 1.46, a quick ratio of 1.14 and a debt-to-equity ratio of 0.15. The stock has a market capitalization of $124.69 billion, a price-to-earnings ratio of 19.81, a PEG ratio of 1.01 and a beta of 0.55.

Sanofi (NASDAQ:SNY - Get Free Report) last issued its quarterly earnings results on Thursday, April 24th. The company reported $0.94 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.90 by $0.04. The business had revenue of $10.41 billion for the quarter, compared to analyst estimates of $9.79 billion. Sanofi had a return on equity of 25.61% and a net margin of 12.77%. The firm's revenue for the quarter was down 11.0% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.78 earnings per share. As a group, equities analysts expect that Sanofi will post 4.36 earnings per share for the current fiscal year.

Sanofi Increases Dividend

The firm also recently declared an annual dividend, which will be paid on Thursday, June 12th. Investors of record on Friday, May 9th will be paid a dividend of $2.0369 per share. This represents a dividend yield of 3.1%. This is an increase from Sanofi's previous annual dividend of $1.48. The ex-dividend date is Friday, May 9th. Sanofi's payout ratio is 57.14%.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.